Overview

The Efect of Azithromicyn on Bronchopulmonary Displasia in Extremely Preterm and Very Preterm Infant

Status:
Recruiting

Trial end date:
2022-05-01

Target enrollment:
0

Participant gender:
All

Summary

This study was to see the effectiveness of azithromycin in preventing the incidence of bronchopulmonary dysphasia in extremely preterm and very premature infants. Inclusion criteria were infants with a gestational age of 25-31 weeks 6 days who experienced respiratory distress and their families had agreed to participate in the study, then randomized. The intervention was in the form of giving azithromycin in the intervention group and no intervention was carried out in the control group and then followed up to 36 weeks PMA

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Indonesia University

Treatments:

Azithromycin

Criteria

Inclusion Criteria:

- premature infant 25-31 weeks 6 days with respiratory distress,

Exclusion Criteria:

- multiple congenital anomaly